GSN’s NIPD test is to detecst several genetic disorders including Down Syndrome with equivalent to chorionic villi sampling (CVS).
The test can be performed on a maternal blood draw in the first trimester of pregnancy prior to 12 weeks gestation.
GSN’s Parental Support testing technology is designed to deliver genetic testing results from tiny quantities of DNA, as little as found in a single cell.
In research studies the technology has also demonstrated success in diagnosing chromosome abnormalities from small traces of fetal DNA found in maternal blood.
Chief investigator of the trial Ronald Wapner said GSN’s approach of pairing biostatistics with molecular testing is unique to achieve clinically useful results.
The randomized trial is scheduled to commence later this year.
